Samsung Bioepis' biosimilar sales in European Union surpassed $180 million in the third quarter of this year, data showed Wednesday.
|Samsung Bioepis headquarters in Songdo, Incheon.|
According to the earnings report of Biogen, Samsung Bioepis' marketing partner in EU, the sales of three biosimilar products – Benepali, Flixabi, and Imraldi -- totaled $183.6 million in the third quarter of 2019, up 36 percent from the same period of last year.
The sales of Benepali (Ingredient: Etanercept) totaled $115 million, and those of Flixabi (Ingredient: Infliximab) and Imraldi (Ingredient: adalimumab) totaled $18.4 million and $49.3 million, respectively.
Total cumulative revenue in the first nine months was $542.2 million, similar to last year's total sales of $ 545.1 million. The company expects to break last year's sales easily this year.
Benepali, the company's flagship product, surpassed the market share of Enbrel, the original drug, in five European countries -- Germany, France, the U.K., Italy and Spain – and has become the top sellers in these markets. Flixabi’s sales have also been rising by about 10 percent every quarter.
Imraldi, which launched in October last year, has maintained its market share in the fierce competition with other Humira's biosimilars, and reached cumulative sales of $149 million.
"About 180,000 patients have received prescriptions for Benepali, Flixabi, and Imraldi, and EU will likely be able to cut healthcare costs by 1.8 billion euros this year thanks to these biosimilars," a Biogen official said in a conference call with Samsung Bioepis.
<© Korea Biomedical Review, All rights reserved.>